Introduction
Thromboembolic disease in the form of deep venous thrombosis (DVT) and pulmonary embolism (PE) is a risk following total knee arthroplasty (TKA). Although prophylactic protocols have been used to prevent thromboembolic disease following TKA in Europe and the United States, the outcome of prophylactic protocols have not yet been assessed in Japanese patients.
The purpose of the present study was to evaluate the prophylactic protocols with unfractionated heparin (UFH) and warfarin in Japanese patients who underwent TKA for osteoarthritis knee in regard to bleeding complications.
The authors evaluated the prophylactic protocols with unfractionated heparin (UFH) and warfarin in Japanese patients who underwent total knee arthroplasty (TKA) for osteoarthritis knee in regard to bleeding complications. Fifty-six patients who underwent TKA for osteoarthritis knee with the use of methylmethacrylate were included. Subcutaneous UFH and warfarin were administered for thromboprophylaxis to the first group of 26 patients. The second group of 30 patients did not receive any pharmacological thromboprophylaxis and were used as controls. No significant differences were found between the 2 groups for operative and postoperative blood loss. There were no cases with major bleeding as a complication, but for 2 cases, the international normalized ratio high value exceeded the remedy limits, and temporary dosage discontinuance was required. There were no clinically important bleeding events in the 2 groups. No heparin-induced thrombocytopenia or warfarin-induced skin necrosis occurred. The authors conclude that the protocol with UFH and warfarin is safe for thromboprophylaxis against deep venous thrombosis and pulmonary embolism after TKA in Japanese patients, but its efficacy can only be resolved with further studies. Keywords: unfractionated heparin; warfarin; Japanese; total knee arthroplasty; bleeding complication; prophylaxis; anticoagulation therapy excluded from this study. Subcutaneous UFH and warfarin were administered for thromboprophylaxis to the first group of 26 patients (group P). The second group of 30 patients (group C) did not receive any pharmacological thromboprophylaxis and were used as the control group. Group C was studied first followed by group P.
All the patients underwent unilateral TKA for osteoarthritis with the use of methylmethacrylate under general anesthesia. All the operations were done by or under the supervision of Kazumasa Kimura.
Postoperatively, all patients had intermittent mechanical compression with pneumatic foot pumps in the recovery room.
Although according to the ACCP guidelines the use of low molecular weight heparin (LMWH) or warfarin is advised for the prevention of DVT, 1 as for LMWH, use for preventive purposes has not been permitted in Japan.
The actual protocol calls for the administration of 5000 units of UFH subcutaneously twice a day, prior to the operations. The first dose was given 1 hour before the operation, and the second dose was given 8 hours after the first dose. On the morning after the operation, 3 mg of warfarin was administered orally. Subsequent doses of warfarin were adjusted to prolong the international normalized ratio (INR) of prothrombin time to between 1.5 and 2.5. The subcutaneous administration of 5000 units of UFH twice a day continued until the INR of prothrombin time reached the remedy limits.
Clinically, we analyzed the duration of the operation, duration of tourniquet, the operative blood loss, and postoperative blood loss. And we also noted any major or minor clinical bleeding complications.
The 2 groups were compared using Student's t test for continuous data. The level of significance was set at P < .05.
Results
The mean age of the 26 patients who received the management for thromboprophylaxis was 75 years (range, 60-83 years). The mean age of the 30 patients who did not receive the thromboprophylaxis was 75 years (range, 64-83 years). There were no significant differences between the 2 groups with regard to age, body mass index (BMI), sex, and type of anesthesia ( Table 1) .
All the patients in the 2 groups underwent unilateral TKA with the use of methylmethacrylate for osteoarthritis knee.
The duration of the operation for group P was, on average, 35 minutes, but there was no significant difference between groups P and C. The duration of tourniquet for group P was, on average, 8 minutes more than that for group C ( Table 1) .
As for the operative blood loss average was 291 mL in group P, and was 217 mL in group C. No significant differences were found between the 2 groups for the operative blood loss. As for the postoperative blood loss average was 284 mL in group P, and was 382 mL in group C. No significant differences were found between the 2 groups for the postoperative blood loss. As for the total blood loss average is defined the total operative blood loss and postoperative blood loss, was 575 mL in group P, and was 586 mL in group C. No significant differences were seen between group P and C for the total blood loss. There were no cases with major bleeding as a complication, but it was noted that the INR high value exceeded the remedy limits in 2 cases, and temporary dosage discontinuance was required. There were no clinically important bleeding events, including ecchymosis of >5 cm, retroperitoneal bleeding, gastrointestinal bleeding, wound hematoma, hematuria, and other site hemorrhages, overall in the 2 groups. No heparin-induced thrombocytopenia or warfarin-induced skin necrosis occurred.
Discussion
The recommendations of the National Institutes of Health Consensus Conference in 1986 endorsed the routine use of anticoagulant prophylaxis for thromboembolic disease after elective total joint replacement and treatment of fractures about the hip. 2 Recent trends in the management of patients undergoing . . . TKA in the United States, . . . present a challenge to orthopedic surgeons who wish to provide their patients with effective prophylaxis for VTE. Despite these challenges, nearly all surgeons participating in the Hip and Knee Registry are providing types of prophylaxis consistent with evidencebased consensus recommendations. 3 The types of prophylaxes used were consistent with the 2001 American College of Chest Physicians recommendations in 91% of patients who had undergone TKA. 3 The introduction of fractionated heparin with a molecular weight in the range of 5000 Da, compared with the average molecular weight of UFH, which is 15 000 Da, has provided another alternative to conventional prophylaxis against thromboembolism. With an enhanced steric affinity for antithrombin III and activated factor X, the fractionated heparin molecule provides a more active agent at an earlier point in the clotting cascade than conventional heparin. Furthermore, by virtue of less binding of plasma protein, the fractionated heparins are more bioavailable, need no monitoring, and have been associated with a lower frequency of both idiosyncratic and autoimmunemediated thrombocytopenia. 4, 5 The ACCP guidelines recommend anticoagulation therapy with LMWH or warfarin as the preventive methods for DVT and PE for TKA patients. 1 The rate of occurrence of DVT during TKA in oriental people is 40% to 50%. 5, 6 However, LMWH use has not been permitted for preventive purposes in Japan. The incidence of DVT and PE is decreased by starting anticoagulation medical therapy before the operation, but the incidence of serious bleeding complications also increases conversely. In Europe and the United States, bleeding complications as a result of anticoagulation therapy is in the range of 2.8% to 2.9%. 7, 8 Despite recent concerns about an increased bleeding risk resulting from the use of anticoagulants in patients who receive spinal or epidural anesthesia, orthopedic surgeons participating in the Hip and Knee Registry increased their use of spinal or epidural anesthesia during the years 1996 through 2001. 3 In Europe and the United States, preventive anticoagulation therapy has become generally accepted, and the complication of bleeding remains a concern in any study. Studies regarding the influence of operation time, the quantity of blood loss, and others factors have not been reported so far in Japan.
We gave anticoagulation therapy to those patients who underwent TKA for osteoarthritis of the knee, for the prevention of DVT and PE, on an individual protocol with UFH and warfarin, and examined them in regard to bleeding complications.
In this study, there were no significant differences between the 2 groups in regard to the duration of operation, operative blood loss, postoperative blood loss, and total blood loss. There were no cases, among Japanese patients, where major bleeding was a complication and no clinically important bleeding events, including ecchymosis of >5 cm, retroperitoneal bleeding, gastrointestinal bleeding, wound hematoma, and other site hemorrhages, in the group that received thromboprophylaxis with UFH and in Japanese patients.
Although this is not a randomized study, the 2 groups were compatible in terms of demographic characteristics; group C thus served as a useful historical control in this study.
In this limited group of studies of the use of UFH and warfarin in TKA, the results appear to favor the use of UFH and warfarin for DVT prophylaxis after TKA in Japanese patients. This experience makes UFH and warfarin our preferred agent for thromboprophylaxis in Japan.
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